Cambridge, UK, 23 March 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE technology has been published in Scientific Reports, a Nature journal. The article, titled "Single-copy detection of somatic variants from solid and liquid biopsy" is freely available online at www.nature.com/articles/s41598-021-85545-3.
As well as detailing the novel technology behind ASPYRE, the publication evidences the flexibility of Biofidelity’s breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer.
Highlights of the publication include:
Veteran Roche executive with more than 35 years of industry experience
Pioneer in the early adoption of polymerase chain reaction (PCR) technology
Cambridge, UK, 15 July 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces the members of its newly-formed Scientific Advisory...